AAOMS Annual Meeting

The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.

The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

The FDA approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA approved Symbicort Inhalation Aerosol 80/4.5 for the treatment for the treatment of asthma in pediatric patients aged 6 to 12 years.

The FDA approved Symbicort Inhalation Aerosol 80/4.5 for the treatment for the treatment of asthma in pediatric patients aged 6 to 12 years.